Thoroughbred Financial Services LLC decreased its stake in Cigna Corp (NYSE:CI) by 33.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,813 shares of the health services provider’s stock after selling 904 shares during the period. Thoroughbred Financial Services LLC’s holdings in Cigna were worth $292,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in CI. Oregon Public Employees Retirement Fund lifted its holdings in shares of Cigna by 42,687.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,752,725 shares of the health services provider’s stock worth $167,000 after purchasing an additional 31,678,514 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Cigna by 59.4% in the 4th quarter. BlackRock Inc. now owns 26,892,201 shares of the health services provider’s stock worth $5,107,369,000 after purchasing an additional 10,021,719 shares during the last quarter. Norges Bank bought a new stake in shares of Cigna in the 4th quarter worth approximately $737,238,000. Macquarie Group Ltd. lifted its holdings in shares of Cigna by 1,413.5% in the 4th quarter. Macquarie Group Ltd. now owns 3,711,240 shares of the health services provider’s stock worth $704,890,000 after purchasing an additional 3,466,030 shares during the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in shares of Cigna by 179.2% in the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 4,456,861 shares of the health services provider’s stock worth $846,447,000 after purchasing an additional 2,860,291 shares during the last quarter. 88.61% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Brian C. Evanko acquired 2,000 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were bought at an average price of $163.40 per share, with a total value of $326,800.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William D. Zollars sold 272 shares of the business’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $168.43, for a total value of $45,812.96. The disclosure for this sale can be found here. 0.80% of the stock is currently owned by insiders.
Cigna stock traded up $2.45 during mid-day trading on Friday, hitting $156.24. 476,271 shares of the company’s stock traded hands, compared to its average volume of 2,819,400. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.70 and a quick ratio of 0.70. The company has a market capitalization of $58.92 billion, a P/E ratio of 10.99, a PEG ratio of 0.77 and a beta of 0.69. Cigna Corp has a one year low of $141.95 and a one year high of $226.60.
Cigna (NYSE:CI) last announced its earnings results on Thursday, May 2nd. The health services provider reported $3.90 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.16. The firm had revenue of $33.43 billion for the quarter, compared to the consensus estimate of $32.79 billion. Cigna had a return on equity of 14.23% and a net margin of 4.11%. The firm’s revenue for the quarter was up 192.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.11 EPS. On average, research analysts expect that Cigna Corp will post 16.54 earnings per share for the current fiscal year.
Several analysts recently issued reports on CI shares. ValuEngine downgraded Cigna from a “hold” rating to a “sell” rating in a report on Thursday, February 28th. UBS Group started coverage on Cigna in a report on Tuesday, April 23rd. They issued a “buy” rating and a $185.00 price target on the stock. Morgan Stanley cut their price target on Cigna from $304.00 to $299.00 and set an “overweight” rating on the stock in a report on Tuesday, February 5th. Goldman Sachs Group reissued a “buy” rating on shares of Cigna in a report on Saturday, February 2nd. Finally, Zacks Investment Research raised Cigna from a “hold” rating to a “strong-buy” rating and set a $171.00 target price on the stock in a research note on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and fifteen have assigned a buy rating to the stock. Cigna presently has a consensus rating of “Buy” and an average price target of $225.85.
TRADEMARK VIOLATION NOTICE: “Thoroughbred Financial Services LLC Sells 904 Shares of Cigna Corp (CI)” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thestockobserver.com/2019/05/17/thoroughbred-financial-services-llc-sells-904-shares-of-cigna-corp-ci.html.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Featured Article: Options Trading – What is a Straddle?
Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corp (NYSE:CI).
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.